MCU Recombinant Monoclonal Antibody [BLR355N]

Rabbit Recombinant Monoclonal

Purified		RefSeq ID	NP_612366.1
Catalog No.	A700-355	Uniprot ID	Q8NE86
Lot No.	1	GeneID	90550

APPLICATIONS	WB, IP, IHC, ICC
SPECIES REACTIVITY	Human, Mouse
AMOUNT	100 µl (50+ tests)
CONCENTRATION	1000 µg/ml
STORAGE/SHELF LIFE	2 - 8°C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Phosphate Buffered Saline (PBS) with 0.09% Sodium Azide, BSA-Free
ISOTYPE	IgG
CLONE #	BLR355N
ORIGIN	USA
PRODUCTION PROCEDURES	Recombinant antibody was purified from cell culture supernatant. Immunogen was a peptide representing a region between residue 300 and 350 of human Mitochondrial calcium uniporter MCU using the numbering given in entry NP_612366.1 (Gene ID 90550).
APPLICATIONS	Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.

Western Blot	1:1,000
Immunoprecipitation	6 µl/mg lysate
Immunohistochemistry	1:100 to 1:500. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.
Immunocytochemistry	1:100 to 1:500. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE cell sections.

APPLICATION NOTES	All western blot analysis is performed using 5% Milk-TBST for blocking and as antibody diluent. Primary antibody is incubated overnight. Western blots of cell lysates are performed using Goat anti-Rabbit IgG Heavy and Light Chain Antibody (A120-101P). Western blots of immunoprecipitates are performed using Goat anti-Rabbit Light Chain HRP Conjugate (A120-113P) with 5% Normal Pig Serum (S100-020) added to the blocking buffer.
IHC HUMAN CONTROLS	Ovarian Carcinoma, Prostate Carcinoma, OVCAR-3 Cells
IHC MOUSE CONTROLS	AML12 Cells
ADDITIONAL INFO	https://www.fortislife.com/p/A700-355 Use the link above to view SDS, a current list of citations, and other product specific information.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.

Michael Spencer, PhD Date: March 28, 2025